表紙:小児ワクチンの世界市場:2019年~2023年
市場調査レポート
商品コード
317310

小児ワクチンの世界市場:2019年~2023年

Global Pediatric Vaccine Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 128 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
小児ワクチンの世界市場:2019年~2023年
出版日: 2019年02月14日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 128 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

Technavioのチームのアナリストは、中低所得国における予防接種に対する意識の高まりが、市場で勢いを増している最新動向であると述べています。

強力な後期パイプラインと新薬承認が市場の主な推進力の1つとなっている一方で、 ワクチンの開発、保管、および取り扱いに関連する課題が市場成長を妨げる大きな要因の1つとなっています。

当レポートでは、世界の小児用ワクチン市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第7章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 共役ワクチンなど
  • 弱毒化生ワクチン
  • トキソイドワクチン
  • 不活化ワクチン
  • 市場機会:製品別

第8章 顧客情勢

第9章 市場セグメンテーション:タイプ別

  • 一価ワクチン
  • 多価ワクチン

第10章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • CSL Limited
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi

第15章 付録

  • 調査方法
  • 略語のリスト
目次
Product Code: IRTNTR30870

About this market

The prevalence of infectious diseases is high in the pediatric population, as the immune system of children is not fully developed. Therefore, infectious diseases are a leading cause of mortality in this population segment. Factors such as rising population as well as environmental and a few genetic factors are contributing to the rapidly growing incidences of infectious diseases. For instance, increased exposure to environmental factors such as ultraviolet radiation is responsible for the suppression of cell-based immunity in children, which makes them susceptible to numerous infectious diseases. Likewise, the rapid increase in birth rates is also a contributing factor to the rise in the number of infectious diseases. The increase in fertility rates is subsequently increasing the risk of maternally acquired infections such as HIV infection. All these factors are contributing to the increase in the prevalence of infectious diseases, which is further driving the market growth. Technavio's analysts have predicted that the pediatric vaccine market will register a CAGR of over 7% by 2023.

Market Overview

Strong late-stage pipeline and new drug approvals

The market contains a significant number of monotherapy- and combination therapy-based vaccines that are currently under the late stages of development and are expected to get approved during the forecast period. These vaccines possess a strong therapeutic potential for the prevention of a large number of infectious diseases and allergies in children. The therapeutic potential of these vaccines can be demonstrated by the results of clinical trials.

Hurdles to optimal use of vaccines

Hurdles such as supply constraints, inadequate vaccine coverage, and lack of knowledge regarding the importance of immunization are restricting the optimal use of vaccines in both developing as well as developed countries. However, the lack of vaccination coverage is responsible for millions of deaths among the pediatric population.

For the detailed list of factors that will drive and challenge the growth of the pediatric vaccine market during the 2019-2023, view our report.

Competitive Landscape

The pediatric vaccine market appears to be moderately concentrated and with the presence of limited vendors. The increasing prevalence of infectious diseases in pediatric population will drive the market growth This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Conjugate vaccines and others - Market size and forecast 2018-2023
  • Live-attenuated vaccines - Market size and forecast 2018-2023
  • Toxoid vaccines - Market size and forecast 2018-2023
  • Inactivated vaccines - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Monovalent vaccines
  • Multivalent vaccines

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • CSL Limited
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Global vaccine market
  • Exhibit 02: Segments of global vaccine market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pediatric vaccines in the pipeline
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Conjugate vaccines and others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Conjugate vaccines and others - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Sales of leading conjugate vaccines 2015-2017 ($ millions)
  • Exhibit 23: Live-attenuated vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Live-attenuated vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Sales of leading live-attenuated vaccines 2015-2017 ($ millions)
  • Exhibit 26: Toxoid vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Toxoid vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Inactivated vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Inactivated vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Market opportunity by product
  • Exhibit 31: Customer landscape
  • Exhibit 32: Market share by geography 2018-2023 (%)
  • Exhibit 33: Geographic comparison
  • Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Incidence rates for malaria 2017 (reported by the World Bank)
  • Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Immunization programs for children
  • Exhibit 46: Recently approved vaccines by the FDA
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: CSL Limited - Vendor overview
  • Exhibit 54: CSL Limited - Business segments
  • Exhibit 55: CSL Limited - Organizational developments
  • Exhibit 56: CSL Limited - Geographic focus
  • Exhibit 57: CSL Limited - Segment focus
  • Exhibit 58: CSL Limited - Key offerings
  • Exhibit 59: GlaxoSmithKline plc - Vendor overview
  • Exhibit 60: GlaxoSmithKline plc - Business segments
  • Exhibit 61: GlaxoSmithKline plc - Organizational developments
  • Exhibit 62: GlaxoSmithKline plc - Geographic focus
  • Exhibit 63: GlaxoSmithKline plc - Segment focus
  • Exhibit 64: GlaxoSmithKline plc - Key offerings
  • Exhibit 65: Merck & Co., Inc. - Vendor overview
  • Exhibit 66: Merck & Co., Inc. - Business segments
  • Exhibit 67: Merck & Co., Inc. - Organizational developments
  • Exhibit 68: Merck & Co., Inc. - Geographic focus
  • Exhibit 69: Merck & Co., Inc. - Segment focus
  • Exhibit 70: Merck & Co., Inc. - Key offerings
  • Exhibit 71: Pfizer Inc. - Vendor overview
  • Exhibit 72: Pfizer Inc. - Business segments
  • Exhibit 73: Pfizer Inc. - Organizational developments
  • Exhibit 74: Pfizer Inc. - Geographic focus
  • Exhibit 75: Pfizer Inc. - Segment focus
  • Exhibit 76: Pfizer Inc. - Key offerings
  • Exhibit 77: Sanofi - Vendor overview
  • Exhibit 78: Sanofi - Business segments
  • Exhibit 79: Sanofi - Organizational developments
  • Exhibit 80: Sanofi - Geographic focus
  • Exhibit 81: Sanofi - Segment focus
  • Exhibit 82: Sanofi - Key offerings
  • Exhibit 83: Validation techniques employed for market sizing